Skip to main content

Perceptive Advisors — Portfolio, Page 8

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

224
Companies
$26.6B
Total invested
$135.1M
Avg. check
23
Industries
Biotechnology 19Health Care 14Therapeutics 12Medical 9Pharmaceutical 7Medical Device 5+17 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 169192 of 224
Marea Therapeutics
June 2024

Marea is a biotechnology company that develops therapies and medications for the treatment of cardioendocrine illness patients.

Biotechnology · San Francisco$190.0M Series B
CARGO Therapeutics
May 2024

CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.

Biotechnology · San Mateo$110.0M Post Ipo Equity
CinDome Pharma
May 2024

CinDome Pharma provides treatment for the millions of people living with the devastating impact of chronic gastroparesis.

Health Care · Cincinnati$40.0M Series B
CereVasc
May 2024

CereVasc is a medical device company focused on improving the treatment of patients with hydrocephalus.

Biotechnology · Auburndale$70.0M Series B
Allogene Therapeutics
May 2024

Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.

Biotechnology · South San Francisco$110.0M Post Ipo Equity
SOPHiA GENETICS
May 2024

SOPHiA GENETICS is a biotechnology firm that aims to support healthcare professionals by maximizing the power of data-driven medicine.

Artificial Intelligence (AI) · Boston$15.0M Post Ipo Debt
Surf Bio
April 2024

Surf Bio develops therapeutic solutions for diabetes, oncology, infectious diseases, and gene therapy.

Biotechnology · Palo Alto$1.6M Grant
Adaptilens
April 2024

Adaptilens is a developer of an accommodating intraocular lens.

Health Care · Boston$17.5M Series A
Neurosterix
April 2024

Neurosterix is a biopharmaceutical firm dedicated to creating allosteric modulators for the treatment of neurological illnesses.

Biopharma · Geneva$65.0M Series A
Stoke Therapeutics
March 2024

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Biotechnology · Bedford$125.0M Post Ipo Equity
Capstan Therapeutics
March 2024

Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.

Biotechnology · San Diego$175.0M Series B
Emulate
March 2024

Emulate creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.

Biotechnology · Boston$47.1M Series F
Akero Therapeutics
March 2024

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

Biotechnology · Cambridge$366.9M Post Ipo Equity
Applied Therapeutics
February 2024

Applied Therapeutics uses drug-development approach to target molecules and pathways that has roles in fatal or debilitating diseases.

Biotechnology · New York$100.0M Post Ipo Equity
Clearside Biomedical
February 2024

Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.

Biotechnology · Alpharetta$15.0M Post Ipo Equity
SpringWorks Therapeutics
December 2023

SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.

Biopharma · Stamford$275.0M Post Ipo Equity
Cerevel Therapeutics
October 2023

Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders.

Biotechnology · Boston$450.0M Post Ipo Equity
Synlogic
September 2023

Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.

Biotechnology · Cambridge$21.0M Post Ipo Equity
Poseida Therapeutics
August 2023

Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.

Biopharma · San Diego$50.0M Post Ipo Equity
Zentalis Pharmaceuticals
June 2023

Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.

Biopharma · New York$235.5M Post Ipo Equity
Kindbody
May 2023

Kindbody is a fertility clinic network and family-building benefits provider for employers.

Employee Benefits · New York$25.0M Series Unknown
VivoSense
January 2023

VivoSense is an advancing clinical research with wearable sensor solutions.

Biotechnology · Newport CoastGrant
Escient Pharmaceuticals
November 2022

Escient Pharmaceuticals is a privately-held biotechnology company focusing on the advancement of G Protein-Coupled Receptor targeted drugs.

Biotechnology · San Diego$120.0M Series C
Willow
September 2022

Willow is a women's healthcare company that develops pumping bras and breast pumps for women.

Commercial · Mountain ViewSeries D

Where Perceptive Advisors invests

Biotechnology19
Health Care14
Therapeutics12
Medical9
Pharmaceutical7
Medical Device5

About Perceptive Advisors's portfolio

How many companies has Perceptive Advisors invested in?

Perceptive Advisors has invested in 224 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Perceptive Advisors invest in?

Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 23 different industry categories.

What is Perceptive Advisors's largest investment?

Among tracked funding rounds, Cerevel Therapeutics received $450.0M in a Post Ipo Equity round. Perceptive Advisors's total known invested capital is $26.6B.

What is the average investment size for Perceptive Advisors?

Perceptive Advisors's average investment size is $135.1M across its portfolio of 224 companies.

What are Perceptive Advisors's most recent investments?

Recent Perceptive Advisors portfolio additions include Marea Therapeutics, CARGO Therapeutics, CinDome Pharma, CereVasc, Allogene Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 224 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →